These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1510438)

  • 1. Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infections.
    Woodnutt G; Berry V; Mizen L
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1427-31. PubMed ID: 1510438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.
    Weiss WJ; Petersen PJ; Murphy TM; Tardio L; Yang Y; Bradford PA; Venkatesan AM; Abe T; Isoda T; Mihira A; Ushirogochi H; Takasake T; Projan S; O'Connell J; Mansour TS
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4589-96. PubMed ID: 15561830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
    Kern W; Kennedy SL; Sachdeva M; Sande ER; Gunderson D; Täuber MG
    Antimicrob Agents Chemother; 1990 May; 34(5):697-701. PubMed ID: 2163241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.
    Coleman K; Griffin DR; Page JW; Upshon PA
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1580-7. PubMed ID: 2817854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of prophylaxis with beta-lactams and beta-lactam-beta-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model.
    Kernodle DS; Kaiser AB
    Antimicrob Agents Chemother; 1993 Apr; 37(4):702-7. PubMed ID: 8494364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad-spectrum beta-lactams for treating experimental peritonitis in mice due to Escherichia coli producing plasmid-encoded cephalosporinases.
    Vimont S; Aubert D; Mazoit JX; Poirel L; Nordmann P
    J Antimicrob Chemother; 2007 Nov; 60(5):1045-50. PubMed ID: 17804425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Abodakpi H; Chang KT; Zhou J; Byerly C; Tam VH
    Clin Microbiol Infect; 2019 Sep; 25(9):1154.e9-1154.e14. PubMed ID: 30664934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYN-1012: a new beta-lactamase inhibitor of penem skeleton.
    Phillips OA; Czajkowski DP; Spevak P; Singh MP; Hanehara-Kunugita C; Hyodo A; Micetich RG; Maiti SN
    J Antibiot (Tokyo); 1997 Apr; 50(4):350-6. PubMed ID: 9186563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies and renal dehydropeptidase stability of the new beta-lactamase inhibitor BRL 42715 in animals.
    Coleman K; Griffin DR; Upshon PA
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1748-52. PubMed ID: 1952842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    Fujita A; Kimura K; Yokoyama S; Jin W; Wachino J; Yamada K; Suematsu H; Yamagishi Y; Mikamo H; Arakawa Y
    PLoS One; 2015; 10(11):e0142366. PubMed ID: 26539828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
    Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
    Santos KVD; Nicoli JR; Martins WA; Coutinho SC; Apolônio ACM; Diniz CG; Carvalho MAR; Farias LM
    J Med Microbiol; 2007 Nov; 56(Pt 11):1576-1579. PubMed ID: 17965366
    [No Abstract]   [Full Text] [Related]  

  • 17. Activity of the beta-lactamase inhibitor BRL 42715 against cephalosporinases produced by Enterobacteriaceae.
    Zhou XY; Kitzis MD; Acar JF; Gutmann L
    J Antimicrob Chemother; 1993 Apr; 31(4):473-80. PubMed ID: 8514645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.
    Mentec H; Vallois JM; Bure A; Saleh-Mghir A; Jehl F; Carbon C
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1883-9. PubMed ID: 1329634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
    Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.